For research use only. All peptides are research chemicals not approved by the FDA for human use. Not for human consumption.
The Growth Hormone Research Stack Explained
The GH research stack — combining a GHRH analogue with a ghrelin receptor agonist — is the most widely studied peptide combination in growth hormone axis research. It leverages two distinct but complementary receptor pathways to produce synergistic GH pulse amplification that neither compound achieves alone. Understanding why researchers use this combination, and how each component contributes, is essential for designing valid GH axis studies.
Component 1: CJC-1295 (GHRH Analogue)
CJC-1295 is a modified analogue of Growth Hormone Releasing Hormone (GHRH), the hypothalamic peptide that stimulates somatotroph cells in the anterior pituitary to produce and release GH. The key modification in the DAC version (Drug Affinity Complex) is the addition of a lysine-maleimide reactive group that binds covalently to endogenous albumin, extending the half-life from ~30 minutes (native GHRH or Mod GRF 1-29) to approximately 6–8 days in animal models.
CJC-1295 DAC works by maintaining elevated GHRH receptor occupancy in the pituitary, increasing the baseline amplitude of GH pulses. Research has used it to study IGF-1 axis modulation, somatotroph cell biology, and GH-dependent changes in lean body mass and bone mineral density in animal aging models.
Component 2: Ipamorelin (GHSR Agonist)
Ipamorelin is a synthetic pentapeptide ghrelin receptor agonist (GHSR-1a). It triggers GH release through a completely separate mechanism from CJC-1295 — by mimicking ghrelin’s action at the growth hormone secretagogue receptor. Its most notable research characteristic is selectivity: unlike GHRP-2 and GHRP-6 (earlier generation GHRPs), Ipamorelin does not meaningfully elevate cortisol or prolactin in research models, making it a cleaner tool for isolated GH secretagogue studies.
Why Researchers Combine Them: Synergistic Mechanisms
CJC-1295 and Ipamorelin act on different receptors (GHRH-R and GHSR-1a respectively) through non-overlapping intracellular signaling cascades. In the somatotroph cell, GHRH-R signaling activates adenylyl cyclase (cAMP pathway) while GHSR-1a signaling activates phospholipase C (IP3/DAG pathway). When both pathways are activated simultaneously, research demonstrates synergistic rather than merely additive GH release — a result that cannot be achieved by increasing the dose of either compound alone.
CJC-1295 DAC vs. Mod GRF 1-29: Which for Your Research?
| Parameter | CJC-1295 DAC | Mod GRF 1-29 (no DAC) |
|---|---|---|
| Half-life | ~6–8 days | ~30 minutes |
| GH release pattern | Sustained elevation | Pulsatile (mimics natural rhythm) |
| Dosing frequency | Weekly or less | Multiple daily doses |
| Best for | IGF-1 axis, chronic studies | Pulsatile GH studies, sleep architecture |
Laboratory Handling
Both CJC-1295 and Ipamorelin are supplied as lyophilized powder. Reconstitute each separately with bacteriostatic water. Store lyophilized stock at -20°C; reconstituted solutions at 2–8°C for up to 28 days. CJC-1295 is pH-sensitive — avoid acidic solvents. Both compounds should be handled with sterile technique and reconstituted in separate vials to maintain independent dosing control.
Related guides: CJC-1295 & Ipamorelin Overview | Peptide Reconstitution Guide
Source CJC-1295 and Ipamorelin → Iron Labs Research Catalog
Regulatory Notice
CJC-1295 and Ipamorelin are research chemicals for laboratory use only. Not approved by the FDA for human or veterinary use. Iron Labs makes no health or therapeutic claims.